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solid malignancies are associated with the development of Pneumocystis jirovecii pneumonia (pJp). 
this study aimed to evaluate the risk factors for pJp among patients with lung cancer. this retrospective 
case-control study compared patients who had lung cancer with pJp (n = 112) or without PJP (n = 336) 
matched according to age, sex, histopathology, and stage. PJP definition was based on (i) positive 
PCR or direct immunofluorescence results for pneumocystis, (ii) clinical symptoms and radiological 
abnormalities that were consistent with a pneumonic process, and (iii) received targeted PJP treatment. 
the development of pJp was associated with radiotherapy (Rtx), concurrent chemoradiotherapy 
(CCRTx), lymphopenia, and prolonged high-dose steroid therapy (20 mg of prednisolone equivalent per 
day for ≥3 weeks). Multivariate analysis revealed independent associations with prolonged high-dose 
steroid therapy (odds ratio [OR]: 1.96, 95% confidence interval [CI]: 1.06–3.63; p = 0.032) and CCRTx 
(OR: 2.09, 95% CI: 1.27–3.43; p = 0.004). Steroid use was frequently related to RTx pneumonitis or 
esophagitis (29 patients, 43.3%). Prolonged high-dose steroid therapy and CCRTx were risk factors for 
pJp development among patients with lung cancer. As these patients had a poor prognosis, clinicians 
should consider pJp prophylaxis for high-risk patients with lung cancer.
Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection caused by the fungus Pneumocystis 
jirovecii1. During 1980–2000, most PJP cases involved patients with acquired immunodeficiency syndrome 
(AIDS), although PJP has become common in non-human immunodeficiency virus (HIV)-infected cases 
because of improvements in AIDS treatment and more patients receiving immunosuppressive therapy2. However, 
non-HIV-infected patients with PJP have an overall mortality rate of approximately 35–55%3–5, compared to 
10–20% among patients with AIDS6.
Hughes et al.7 reported that the incidence of PJP in acute lymphoblastic leukemia (ALL) ranged from 22% to 
45%, depending on the chemotherapy used and the stage of leukemia. Another study also reported that without 
prophylaxis, PJP rates may approach 25% among patients with non-Hodgkin’s lymphoma8. In a recent study, 
PJP incidence of acute leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma was estimated 
to be >45 cases per 100,000 patient year, whereas PJP incidence of solid tumors was <25 cases per 100,000 
patient-year9. Possible explanations of higher incidence of PJP in hematologic malignancies are related to high 
intensity of chemotherapy7 and severely impaired immune function10. After routine performance of prophylaxis 
using trimethoprim-sulfamethoxazole (TMP-SMX), incidence of PJP among patients with hematologic malig-
nancies has shown remarkable decrease11.
Although the exact incidence of PJP in solid tumors still remains unknown, recent reports have reported PJP 
cases in lung cancer, which is the most common cause of solid malignancy-related death3,9,12. However, little is 
known about the risk factors for PJP development and who would benefit from PJP prophylaxis in lung cancer 
patients. Therefore, this study aimed to evaluate the risk factors for PJP among patients with lung cancer.
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patients and Methods
study design and population. Electronic medical records from the Severance Hospital (a 2,500-bed ter-
tiary referral hospital in South Korea) were searched to identify 3,877 patients with lung cancer who underwent 
surgery, chemotherapy (CTx), and/or radiotherapy (RTx) between January 2013 and December 2016. Among 
these patients, 311 patients had received treatment for PJP using intravenous and/or oral TMP-SMX (trimeth-
oprim: 15–20 mg/kg/day, sulfamethoxazole: 75–100 mg/kg/day). However, cases were excluded if they had an 
unsatisfactory definition of PJP (n = 188), other cancers (n = 7), organ transplantation (n = 3), or HIV infection 
(n = 1). Thus, records from 112 patients with confirmed lung cancer and PJP were matched 1:3 with control 
patients (n = 336, lung cancer without PJP) according to age, sex, histopathology, and stage using exact match 
modeling (Fig. 1). Treatment modalities of lung cancer, including types of chemotherapy, were determined by 
relevant physician on a case-by-case basis, and treatment principles were based on national comprehensive cancer 
network (NCCN) guideline over study period13,14.
PJP Definition.  PJP was considered present when the patient fulfilled three conditions. The first condition 
was a positive result for Pneumocystis jirovecii using either real-time PCR testing or direct immunofluorescence 
testing of spontaneous sputum, induced sputum, bronchoalveolar lavage (BAL), or tissue samples. The real-time 
PCR assay was performed with the AmpliSens Pneumocystis jirovecii-FRT PCR kit (Moscow, Russia), which is a 
qualitative test based on the endogenous control, the β-globin gene. Ten-microliter DNA samples were added in 
each reaction tubes. PCRs were performed on the Bio-Rad CFX-96 real-time PCR system (Bio-Rad, Hercules, 
CA) according to the manufacturer’s instruction. The second condition was the presence of lung infiltration dur-
ing chest radiography or computed tomography (CT)10,15,16. The third condition was clinical symptoms of PJP and 
PJP treatment during their hospitalization. We defined the prophylaxis group as those without a PJP diagnosis 
who received medication to prevent PJP.
Data collection. Demographic and clinical data were collected through a chart review. The lowest total lym-
phocyte count was selected from the 2 weeks before the PJP diagnosis (PJP group) or during the follow-up period 
(control group), and lymphopenia was defined as <1,000 cells/µL17. The daily dosage of steroids was expressed in 
prednisolone equivalents, and the continuous maximum use of steroids was recorded as the cumulative steroid 
dose. We did not consider intermittent steroid use (e.g., as emesis prophylaxis during CTx), or steroid use that was 
stopped at >1 month before the PCP diagnosis, in order to more accurately account for the effect of steroid treat-
ment on PJP development18. Steroid dosage during the last 2 weeks before the PJP diagnosis was compared to the 
dosage during the preceding weeks, and changes during the 2 last weeks were categorized as maintained, increased, 
tapered, or stopped17. Adjunctive steroid use during PJP treatment was defined a high-dose (≥60 mg/day 
prednisolone equivalent), low-dose (<60 mg/day prednisolone equivalent), or absent19. The 60-mg cut-off 
was selected because it was the lowest effective dose in controlled trials for HIV-infected patients with PJP1,20. 
RTx-induced pneumonitis was diagnosed based on the patients’ symptoms (low-grade fever, dry cough, dysp-
nea, or chest pain) and radiological manifestations21,22. Radiation-induced esophagitis was also defined based on 
clinical symptoms (dysphagia, odynophagia, and substernal discomfort)23. Data from chest radiography and CT 
were evaluated independently by one radiologist at the PJP diagnosis, and then independently confirmed by two 
of the authors (EH Lee, MS Park). Medical records related to risk factors for PJP development were studied until 
PJP development in PJP patients, whereas those in controls were studied until death, transfer to another hospital, 
or December 2016.
Figure 1. Flowchart of study patients. TMP-SMX; trimethoprim-sulfamethoxazole, PJP; pneumocystis jirovecii 
pneumonia, HIV; human immunodeficiency virus.
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statistical analysis. Normally distributed continuous variables were reported as mean ± standard devi-
ation, while non-normally distributed variables were reported as median (range). Continuous variables were 
analyzed using the Student t-test or the Mann-Whitney test. Categorical variables were reported as number and 
percentage, and compared using the chi-square test or Fisher’s exact test. The independent risk factors for PJP 
development were evaluated using conditional logistic regression modeling based on the matched paired data, 
and the results were reported as odds ratios (ORs) and 95% confidence intervals (CIs). A two-tailed P-value of 
<0.05 was considered statistically significant. All analyses were performed using SAS software (version 9.4; SAS 
Inc., Cary, NC).
ethics. The research protocol was approved by the Institutional Review Board (IRB) of Severance Hospital 
(IRB No. 4-2017-0431). The need for informed consent was waived due to the retrospective nature of the study. 
All methods were carried out in accordance with relevant guidelines and regulations.
Results
Clinical characteristics and outcomes for pJp. The most common symptom of PJP was dyspnea 
(71.4%), followed by fever (27.7%) and cough (23.2%) (Table 1). The median respiratory symptom duration was 
3 days (range: 1–20 days). Sixty-seven patients (59.8%) received steroids within 1 month before developing PJP. 
The most common reasons for steroid treatment were RTx complications like RTx pneumonitis or esophagitis (29 
patients, 43.3%), relief of tumor infiltration symptoms (24 patients, 35.8%) such as increased intracranial pres-
sure, bronchus obstruction, spinal cord compression and adrenal insufficiency (8 patients, 11.9%). Six patients 
(8.9%) received steroids because of exacerbated underlying lung disease. At the PJP diagnoses, 33 patients (49.3%) 
had a maintained dosage, 23 patients (34.3%) had a tapered dosage, and 11 patients (16.4%) had stopped steroid 
Characteristics (N = 112) Data
Age (years), median (range) 69 (42–88)
Sex, male, n (%) 93 (83.0)
Time from diagnosis of lung cancer (days), median (range) 197 (25–1114)
Time from respiratory symptom onset (days), median (range) 3 (1–20)
Respiratory symptom at admission, n (%)
  Dyspnea 80 (71.4)
  Fever 31 (27.7)
  Cough 26 (23.2)
  Sputum 22 (19.6)
  Others* 16 (14.3)
Patients receiving PJP prophylaxis, n (%) 3 (2.7)
Steroid use, n (%) 67 (59.8)
Reasons for steroid use, n (%)
  RTx complication (RTx pneumonitis, RTx induced esophagitis) 25 + 4/67 (43.3)
  IICP control for brain metastasis 16/67 (23.9)
  Adrenal insufficiency 8/67 (11.9)
  Underlying ILD or COPD exacerbation 6/67 (8.9)
  Bronchus obstruction due to tumor infiltrate 4/67 (6.0)
  Cord compression due to spine metastasis 4/67 (6.0)
Maintained, n (%) 33/67 (49.3)
Tapered, n (%) 23/67 (34.3)
Stopped, n (%) 11/67 (16.4)
Chest x-ray findings at admission, n (%) 112 (100)
  Diffuse interstitial infiltrate, n (%) 75/112 (66.9)
  Unilateral (or focal) interstitial infiltrates, n (%) 26/112 (23.2)
  Focal consolidation, n (%) 11/112 (9.8)
Chest CT scan findings, n (%)† 92/112 (82.1)
  Diffuse ground glass attenuation, n (%) 61/92 (66.3)
  Focal ground glass attenuation, n (%) 20/92 (21.7)
  Focal consolidation, n (%) 7/92 (7.6)
  Others, n (%)§ 4/92 (4.4)
Table 1. Clinical characteristics for PJP among patients with lung cancer. Data are presented as median (range) 
or numbers (percentages) unless otherwise indicated. *Hemoptysis, chest pain, general weakness, poor oral 
intake. †20 patients could not take the CT scan due to poor general condition and high oxygen demand. §Cystic 
lesion, combination of ground glass attenuation and consolidation, solitary or multiple nodules, linear reticular 
opacities. PJP, pneumocystis jirovecii pneumonia; RTx, radiotherapy; IICP, increased intracranial pressure; ILD, 
interstitial lung disease; COPD, chronic obstructive pulmonary disease.
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treatment. The most common findings were diffuse interstitial infiltrates during radiography (66.9%) and bilateral 
ground-glass attenuation during CT (66.3%). Focal consolidation and ground-glass opacities were also detected.
Table 2 shows treatment outcomes of PJP patients with lung cancer. All patients had received TMP-SMX, 
although 7 patients (6.3%) required second-line medication due to progression of PJP despite TMP-SMX therapy 
(primaquine and clindamycin in 6 cases, pentamidine in 1 case). Seventy-five patients (67%) received high-dose 
adjunctive steroids during PJP treatment, 26 patients (23.2%) received low-dose adjunctive treatment, and 11 
patients (9.8%) did not receive adjunctive steroids. The median duration of PJP treatment was 13 days (range: 
2–89 days), and 69 of the 112 patients (61.6%) died during PJP treatment (respiratory failure: 72.5%, cancer pro-
gression: 14.5%, and respiratory failure with cancer progression: 13.0%). Among the 69 deaths, 47 deaths (68.1%) 
involved a do-not-resuscitate and do-not-intubate order, and only 6 patients (8.7%) had a full code status.
Baseline characteristics of patients according to pJp status. Table 3 shows the clinical characteris-
tics of the matched patients with and without PJP. The median patient age was 69 years (range: 42–88), and most 
patients were men (83%). The most frequent histopathological types were adenocarcinoma (46.4% vs. 49.4%), 
squamous cell carcinoma (36.6% vs. 35.7%), and small cell lung cancer (12.5% vs. 14.3%). Approximately 75% of 
the patients had stage IV lung cancer. More than 90% of the patients received CTx (94.6% vs. 92.6%), although 
the control group had a longer median CTx duration than the PJP group (123 days vs. 97 days). The types and 
frequency of chemotherapeutic agents showed no statistical difference between PJP group and control group. RTx 
or concurrent chemoradiation therapy (CCRTx) were more common in the PJP group, compared to the control 
group (RTx: 77.7% vs. 64.3%, p = 0.009; CCRTx: 39.3% vs. 21.7%, p < 0.001). Surgery was more common in the 
control group (11.6% vs. 23.8%, p = 0.006). The median daily steroid dose and proportion of steroid use were sim-
ilar in the two groups (59.8% vs. 55.4%, p = 0.409). The median cumulative steroid dose tended to be higher in the 
PJP group (915 mg vs. 754 mg, p = 0.062) and the duration of steroid use was significantly longer in the PJP group 
(42 days vs. 26.5 days, p = 0.005). Patients with prolonged high-dose steroid use (20 mg of prednisolone equiv-
alent per day for ≥3 weeks) were more common in the PJP group, compared to the control group (30 patients 
[26.8%] vs. 47 patients [14%], p = 0.002). The mean lymphocyte counts were 425/µL (range: 60–1,920/µL) in 
the PJP group and 540/µL (range: 10–2,730/µL) in the control group. The PJP group had a higher proportion of 
patients with lymphopenia (92% vs. 82.1%, p = 0.013). Only 30 of the 448 cases and controls (6.7%) received PJP 
prophylaxis, which was less frequent in the PJP group, compared to the control group (3 patients [2.7%] vs. 27 
patients [8%], p = 0.049).
Risk factors for pJp. In the univariate analyses (Table 4), PJP development was significantly associated with 
RTx (OR: 1.95, 95% CI: 1.18–3.25; p = 0.001), CCRTx (OR: 2.59, 95% CI: 1.58–4.25; p < 0.001), lymphopenia 
(OR: 2.68, 95% CI: 1.23–5.82; p = 0.013), and prolonged high-dose steroid therapy (OR: 2.49, 95% CI: 1.42–4.37); 
p = 0.002). PJP development was inversely but non-significantly associated with TMP-SMX prophylaxis (OR: 
0.33, 95% CI: 0.10–1.09; p = 0.068). In the multivariate analyses, PJP development was independently associated 
with prolonged high-dose steroid therapy (OR: 1.96, 95% CI: 1.06–3.63; p = 0.032) and CCRTx (OR: 2.09, 95% 
CI: 1.27–3.43; p = 0.004). Surgery also was inversely associated with PJP development in the multivariate analysis 
(OR: 0.42, 95% CI: 0.22–0.79; p = 0.008), although this is likely because patients who were able to undergo surgery 
would be less likely to receive CTx or RTx for their early-stage cancer.
Treatment outcomes (N = 112) Data
Treatment regimen
  TMP-SMX alone, n (%) 105/112 (93.7)
  TMP-SMX prior to primaqiune + clinadamycin, n (%) 6/112 (5.4)
  TMP-SMX prior to pentamidine, n (%) 1/112 (0.9)
Adjunctive steroid, n (%)
  High dose, ≥60 mg/day prednisolone equivalent 75/112 (67.0)
  Low dose, <60 mg/day prednisolone equivalent 26/112 (23.2)
  Not used 11/112 (9.8)
Duration of PJP treatment (days), median (range) 13 (2–89)
Death during PJP Treatment, n (%) 69/112 (61.6)
Immediate cause of death
  Respiratory failure due to PJP 50/69 (72.5)
  Cancer progression 10/69 (14.5)
  Respiratory failure due to PJP + cancer progression 9/69 (13.0)
Code status
  Full code 6/69 (8.7)
  DNR + intubation 16/69 (23.2)
  DNR including DNI 47/69 (68.1)
Table 2. Treatment outcomes for PJP among patients with lung cancer. Data are presented as median (range) 
or numbers (percentages) unless otherwise indicated. PJP, pneumocystis jirovecii pneumonia; TMP-SMX, 
trimethoprim-sulfamethoxazole; DNR, do not resuscitate; DNI, do not intubate.
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Discussion
Lung cancer is the most common cause of cancer death worldwide although the survival rate has improved due 
to the use of novel targeted therapies plus conventional therapies24. Disease progression itself may have influ-
enced the prognosis and patient’s survival, infection and pneumonia are typically associated with poor prognoses 
among these immunocompromised patients25. Bacterial pneumonia is relatively common in this setting, com-
pared to PJP, although recent studies have also indicated that PJP occurs among patients with solid malignancies, 
such as lung cancer3,26–28. Thus, the present study compared patients who had lung cancer with or without PJP, 
and the results revealed that prolonged high-dose steroid use and CCRTx were independent risk factors for devel-
oping PJP in this setting.
Long-term corticosteroid use is a known risk factor for developing PJP among non-HIV-infected patients29,30, 
which is likely related to their effects on T-cell immunity8. However, the present study detected a relatively small 
proportion of patients with steroid use and relatively low cumulative steroid dose in the PJP group, compared to 
the findings from previous studies12,18. This discrepancy may be related to differences in the definition of steroid 
use and other risk factors that might influence PJP development. For example, the present study excluded cases 
from the steroid use group if the steroid treatment was stopped at >1 month before the PJP diagnosis. In addition, 
we excluded cases with intermittent steroid use, and compared the maximum cumulative continuous steroid dose 
in the PJP and control groups. As a result, we did not detect a significant inter-group difference in daily steroid 
dose or cumulative maximum dose. However, when we categorized the patients according to daily steroid dose 
Variable PJP (n = 112)
Without PJP 
(n = 336) P
Age (years), median (range) 69 (42–88) 69 (42–88) 0.995
Sex, male, n (%) 93 (83.0) 279 (83.0) 1.0
Histopathology, n (%) 0.286
  Adenocarcinoma 52 (46.4) 166 (49.4)
  Squamous cell carcinoma 41 (36.6) 120 (35.7)
  Small cell lung cancer 14 (12.5) 48 (14.3)
Stage, n (%) 0.586
  I + II 8 (7.2) 32 (9.6)
  III 21 (18.7) 52 (15.5)
  IV 83 (74.1) 251 (74.9)
Brain metastasis, n (%) 38 (33.9) 94 (28.0) 0.231
Surgery, n (%) 13 (11.6) 80 (23.8) 0.006
CTx, n (%) 106 (94.6) 311 (92.6) 0.452
  Cisplatin 43 (40.6) 125 (40.3) 0.965
  Carboplatin 64 (60.4) 168 (54.2) 0.268
  Gemcitabine 23 (21.7) 69 (22.2) 0.917
  Docetaxel 12 (11.3) 25 (8.1) 0.309
  Paclitaxel 33 (31.1) 95 (30.6) 0.925
  Pemetrexed 32 (30.2) 99 (31.9) 0.738
  Etoposide 19 (17.9) 48 (15.5) 0.555
  Molecularly targeted TKIs 29 (27.4) 107 (34.5) 0.189
  Immune checkpoint inhibitors 10 (9.4) 17 (5.5) 0.157
CTx duration (days), median (range) 97 (0–1106) 123 (0–1393) 0.044*
RTx, n (%) 87 (77.7) 216 (64.3) 0.009
RTx cumulative dose (Gy), median (range) 54 (0–143) 60 (3–205) 0.023*
CCRTx, n (%) 44 (39.3) 73 (21.7) <0.001
Steroid use, n (%) 67 (59.8) 186 (55.4) 0.409
Steroid ≥20 mg/d and ≥3 wks, n (%) 30 (26.8) 47 (14.0) 0.002
Steroid, daily dose (mg), median (range)† 25 (5–100) 25 (2–156.2) 0.476
Steroid, duration (days), median (range)† 42 (6–210) 26.5 (2–1363) 0.005
Steroid, cumulative dose (mg), median (range)† 915 (120–5250) 754 (30–6815) 0.062
Lymphopenia (<1000 cells/µL), n (%) 103 (92.0) 276 (82.1) 0.013
Lymphocyte count (cells/µL), median (range) 425 (60–1920) 540 (10–2730) 0.008*
PJP prophylaxis, n (%) 3 (2.7) 27 (8.0) 0.049
Table 3. Baseline characteristics of lung cancer patients according to PJP status. Data are presented as median 
(range) or numbers (percentages) unless otherwise indicated. *Compared using Mann-Whitney U test. †Data 
were obtained from 253 patients who ever used steroid during study period. Steroid; prednisolone or equivalent 
dose. PJP, pneumocystis jirovecii pneumonia; CTx, chemotherapy; TKI, tyrosine kinase inhibitor; RTx, 
radiotherapy; CCRTx, concurrent chemoradiotherapy.
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and duration, we found that a specific cut-off value (20 mg of prednisolone equivalent per day for ≥3 weeks) was 
independently associated with PJP development, although the area under the curve was low (0.568).
Previous studies have indicated that RTx could be a risk factor for PJP development5,31. In this study, univari-
ate analysis revealed the RTx was associated with PJP development, this association was statistically insignificant 
in the multivariate analysis. Other reports have indicated that specific chemotherapeutic agents, such as fluo-
rouracil, bleomycin, asparaginase, fludarabine, and gemcitabine, were associated with the risk of PJP develop-
ment3,27,28,32. Patients who receive high-dose steroids with cytotoxic CTx or RTx could be even more vulnerable to 
PJP development28. In the current study, specific chemotherapeutic agents did not increase the risk of PJP, while 
CCRTx was significantly associated with PJP development in multivariate analysis (p = 0.004).
The present study revealed that most patients who developed PJP had decreased lymphocyte counts (median: 
425/µL, range: 60–1,920/µL), which was a significant risk factor in the univariate analysis but not in the multivar-
iate analysis. Mansharamani et al. have suggested that a cut-off value of 300 CD4+ cells/µL would include 91% of 
PJP cases among HIV-negative patients, which is a high-risk group, although 39–46% of individuals who received 
long-term corticosteroid therapy also had CD4+ counts of <300/µL33. Moreover, the accuracy of this biomarker 
is poorly characterized for non-HIV-infected patients, which limits its use in that population, although it is an 
accurate method for assessing PJP risk among patients with AIDS18,34.
The characteristics of our patients with PJP and lung cancer were different from those of non-HIV-infected 
patients in other studies. The most common clinical symptom was dyspnea in the present study, and our patients’ 
respiratory symptoms tended to manifest quickly, which was also observed in previous studies12,35. However, the 
frequencies of fever and cough were relatively low in our study, compared to previous studies12,35. This discrep-
ancy may be related to reduced immunity caused by CTx and/or RTx, which could mask signs of infection. The 
reported prognosis of PJP is poorer among non-HIV-infected patients, compared to HIV-infected patients36, 
although we observed a much higher mortality rate during PJP treatment (approximately 60%), compared to 
other studies conducted in non-HIV-infected patients5,35. In this current study, most patients received first-line 
TMP-SMX treatment and approximately 67% of the patients with PJP also received high-dose adjunctive steroids 
during their PJP treatment19. Thus, the poor prognosis may be related to the advanced lung cancer and/or the 
weakened general condition of patients who receive CTx and/or RTx before developing PJP. It is also possible 
that the large proportion of patients with do-not-resuscitate or do-not-intubate statuses was responsible for the 
relatively high mortality rate among our patients with lung cancer and PJP.
Among HIV-infected patients, TMP-SMX prophylaxis is highly effective for preventing PJP34. A recent 
meta-analysis also indicated that, among solid organ transplant recipients and patients with hematological malig-
nancies, TMP-SMX treatment was associated with reductions in the occurrence of PJP (RR: 0.09, 95% CI: 0.02–
0.32) and PJP-related mortality (RR: 0.17, 95% CI: 0.03–0.94), which suggests that PJP prophylaxis is warranted 
when adult patients have a >3.5% risk of PJP11. Several studies have indicated that solid malignancies are asso-
ciated with an increased risk of PJP3,12,28,37, although there are no clinical data supporting the routine use of PJP 
prophylaxis for patients with solid tumors. The American Thoracic Society recommends considering prophylaxis 
when immunocompromised patients (including patients with solid tumors) receive prolonged high-dose corti-
costeroid treatment (20 mg of prednisolone equivalent per day for ≥4 weeks), although it acknowledges that this 
recommendation is based on a low level of evidence38. The present study also confirmed that PJP prophylaxis is 
not routine for patients with lung cancer, even for patients who are receiving prolonged high-dose steroid therapy. 
As PJP prophylaxis can significantly reduce mortality among patients with other diseases, it may be beneficial to 
provide PJP prophylaxis to high-risk patients with lung cancer. For example, prolonged high-dose steroid therapy 
and CCRTx were possible risk factors for PJP among patients with lung cancer, and the most common reason for 
steroid use was radiation-induced pneumonitis, which is relatively common after CCRTx (vs. RTx)21. Therefore, 
it seems reasonable to use PJP prophylaxis for patients who are receiving prolonged high-dose steroid treatment 
and CCRTx.
The present study has several limitations. First, the single-center retrospective design is associated with known 
risks of bias, and we were unable to collect exact information regarding symptom presentation or duration before 
the PJP diagnosis. Thus, our findings may not be generalized to other centers or patient populations. Second, 
proportion of surgery in PJP cases and controls are somewhat different, suggesting the possibility of inadequate 
cancer stage matching. Third, we used PCR and immunofluorescence data to diagnose PJP, and our data may 
Variable
Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Brain metastasis 1.27 (0.80–2.02) 0.307
Surgery 0.41 (0.22–0.73) 0.006 0.42 (0.22–0.79) 0.008
CTx 1.43 (0.57–3.60) 0.450
RTx 1.95 (1.18–3.25) 0.001
CCRTx 2.59 (1.58–4.25) <0.001 2.09 (1.27–3.43) 0.004
Lymphopenia (<1000 cells/µL) 2.68 (1.23–5.82) 0.013
Steroid ≥20 mg/d and ≥3 wks† 2.49 (1.42–4.37) 0.002 1.96 (1.06–3.63) 0.032
PJP prophylaxis 0.33 (0.10–1.09) 0.068
Table 4. Clinical risk factors for PJP development. †Prednisolone or equivalent dose. PJP, pneumocystis jirovecii 
pneumonia; CTx, chemotherapy; RTx, radiotherapy; CCRTx, concurrent chemoradiotherapy.
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include false-positive results, as a confirmed PJP diagnosis generally requires special microbiological staining 
of respiratory specimens39. However, non-HIV-infected patients have a lower overall organism burden40 com-
pared to HIV-infected patients, and conventional staining methods might have provided lower sensitivity and 
false-negative results. A meta-analysis of PCR-based PJP diagnosis revealed a sensitivity of 99% and specificity 
of 92% among non-HIV-infected patients, and that 31.8% of patients with false-positive results had or subse-
quently developed PJP41. Thus, patients with a positive PCR result require careful follow-up and/or PJP treatment. 
Other reports have also suggested that PCR assays for PJP are sensitive and increase the diagnostic yield among 
non-HIV-infected immunocompromised patients16,42,43. Therefore, to reduce the likelihood of false-positive 
results, we only included patients with symptoms of acute pulmonary infiltrates, such as cough, dyspnea, and 
radiological abnormalities.
Despite its limitations, the present study also has several strengths. To the best of our knowledge, this is the 
first case-control study of PJP among patients with lung cancer. In addition, we matched the patients with PJP to a 
relatively large number of control patients, which provides a clearer perspective regarding the risk factors for PJP 
development among patients with lung cancer. Furthermore, our findings may be useful for identifying high-risk 
patients with lung cancer who should receive PJP prophylaxis. Nevertheless, multicenter randomized controlled 
trials are needed to examine the value of PJP prophylaxis in this setting.
Conclusion
In conclusion, the present study revealed that prolonged high-dose steroid therapy (20 mg of prednisolone equiv-
alent per day for ≥3 weeks) and CCRTx were risk factors for PJP development among patients with lung cancer. 
These patients had a very poor prognosis. Furthermore, the most common reasons for the steroid treatment were 
CCRTx or RTx-induced pneumonitis. Therefore, clinicians should consider PJP prophylaxis for high-risk patients 
with lung cancer.
Data Availability
All datasets generated and analysed during this study are available from the corresponding author on reasonable 
request.
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